AstraZeneca Covid Vaccine Backed by EU Regulators

The European Medicines Agency (EMA) has emphasized the benefits of the AstraZeneca vaccine despite concerns about blood clots. This message contradicts some European governments' hesitations, leading to reputational damage for AstraZeneca. The uptake of AstraZeneca is lower compared to other vaccines like Pfizer, posing a problem amid high infection rates. The situation is complicated by political and communication challenges, with public trust being a significant issue.

What is the significance of the upcoming decision regarding the AstraZeneca vaccine?

What role does public perception play in the distribution of the AstraZeneca vaccine?